Home/Indications/Immunology/Rheumatoid Arthritis

Rheumatoid Arthritis

Immunology 13 original drugs

Novel Drugs

Reformulations

Drug Targets

Immunology indication. Rheumatoid Arthritis has 13 FDA-approved novel treatments, led by Johnson & Johnson, with 147 active industry clinical trials across 18 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Rheumatoid Arthritis Market Leaders

Companies with the most FDA-approved novel Rheumatoid Arthritis drugs.

Phase 3 Readouts Pro

3 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Upadacitinib

AbbVie

Estimated · fresh NCT05814627

Q4 2026

TLL-018

Hangzhou Highlightll Pharmaceutical Co., Ltd

Estimated · stale NCT06887127

Q3 2025

LNK01001

Lynk Pharmaceuticals Co., Ltd

Completed · awaiting NCT06276998

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Rheumatoid Arthritis Treatments by Mechanism

Top 12 mechanisms across 131 industry trials with a known mechanism of action.

See full pipeline →

Janus Kinase Inhibitor

14 trials 1 active 2 sponsors

Selective T Cell Costimulation Modulator

13 trials 1 active 3 sponsors

TNF

10 trials 1 active 4 sponsors

CD20-directed Cytolytic Antibody

6 trials 1 active 6 sponsors

Tumor Necrosis Factor Blocker

36 trials 21 sponsors

Interleukin-6 Receptor Antagonist

33 trials 4 sponsors

Folate Analog Metabolic Inhibitor

9 trials 3 sponsors

Calcineurin/FKBP-12

4 trials 1 sponsor

Corticosteroid

2 trials 2 sponsors

Interleukin-17 Receptor A Antagonist

2 trials 1 sponsor

Purine Antimetabolite

1 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Rheumatoid Arthritis Clinical Pipeline by Phase

709 industry-sponsored trials across 219 sponsors

View full landscape →

Showing 60 of 60 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eisai Korea Inc.	Filgotinib Maleate	—	COMPLETED	2026-01-21	NCT06625242
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2025-05-28	NCT03915964
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2025-05-19	NCT04086745
Astellas	tacrolimus	Calcineurin/FKBP-12	COMPLETED	2020-06-16	NCT03737708
Sanofi	SARILUMAB	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2019-07-31	NCT03449758
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2019-03-28	NCT02557100
Pfizer	CP-690,550	—	COMPLETED	2018-11-19	NCT02831855
AbbVie	Adalimumab	TNF	COMPLETED	2018-05-03	NCT02198651
Roche	Prednisone	Corticosteroid [EPC]	COMPLETED	2018-02-09	NCT02573012
Dong-A ST Co., Ltd.	CELBESTA®	—	COMPLETED	2017-12-26	NCT02780323
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2016-12-26	NCT01758198
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-07-29	NCT02682823
Roche	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-03-25	NCT01331837
UCB Pharma SA	Certolizumab Pegol (CZP)	—	COMPLETED	2015-11	NCT01500278
Jiangsu Simcere Pharmaceutical Co., Ltd.	Iguratimod	—	COMPLETED	2015-08	NCT01554917
AbbVie (prior sponsor, Abbott)	adalimumab	TNF	COMPLETED	2015-07	NCT01162421
Chong Kun Dang Pharmaceutical	Tacrolimus with Methotrexate	—	COMPLETED	2015-06	NCT01746680
Astellas	Tacrolimus	Calcineurin/FKBP-12	COMPLETED	2015-05-11	NCT01511003
UCB Italy s.p.a.	Certolizumab pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-05	NCT01443364
Mundipharma Korea Ltd	Lodotra®	—	COMPLETED	2015-04	NCT02072200
Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-03	NCT01578850
Mundipharma Pte Ltd.	Buprenorphine transdermal patch	—	COMPLETED	2015-01	NCT01961271
Mundipharma Pharmaceuticals Sdn. Bhd.	Buprenorphine Transdermal Patch	—	COMPLETED	2015-01	NCT02519387
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2014-07	NCT01149057
Roche	methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2014-05	NCT01399697
Amgen	Etanercept via Autoinjector A	—	COMPLETED	2014-03-04	NCT01875991
Pfizer	Phase 1: Etanercept	—	COMPLETED	2013-04	NCT00848354
Roche	methylprednisolone	—	COMPLETED	2013-03	NCT01219933
Amgen	etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2013-02	NCT01313208
Roche	rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2013-01-06	NCT01382940
AbbVie (prior sponsor, Abbott)	Adalimumab	TNF	COMPLETED	2013-01	NCT01185288
Amgen	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2012-12	NCT00654368
UCB Pharma	Certolizumab Pegol (CZP)	—	COMPLETED	2012-10	NCT01255761
Pfizer	etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2012-06	NCT00913458
Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2012-06	NCT00858780
Roche	rituximab [MabThera/Rituxan]	—	COMPLETED	2012-05-16	NCT01000610
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2012-03	NCT01195272
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2012-01	NCT01119859
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2011-12	NCT01089023
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2011-12	NCT01163747
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2011-09	NCT01034397
Astellas	Tacrolimus	Calcineurin/FKBP-12	COMPLETED	2011-06	NCT01224041
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2011-02-14	NCT00996203
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2010-07	NCT02010216
UCB Pharma	Certolizumab pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2010-06	NCT00993668
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2010-05	NCT01010503
Wyeth is now a wholly owned subsidiary of Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2010-03	NCT00768053
Centocor Ortho Biotech Services, L.L.C.	Infliximab	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2010-01	NCT00714493
Astellas	Tacrolimus	Calcineurin/FKBP-12	COMPLETED	2009-08	NCT01224418
DePuy International	—	—	TERMINATED	2018-02-08	NCT01635166
DePuy International	—	—	TERMINATED	2016-01-01	NCT01134445
Amgen	Etanercept	Tumor Necrosis Factor Blocker [EPC]	TERMINATED	2015-06-11	NCT01927757
Roche	Methotrexate (stable dose)	—	TERMINATED	2015-02	NCT01661140
Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	TERMINATED	2014-08	NCT01783015
Roche	tocilizumab [RoActemra/Actemra]	—	TERMINATED	2013-01	NCT01251120
Roche	tocilizumab [RoActemra/Actemra]	—	TERMINATED	2012-08	NCT01283971
Roche	rituximab [MabThera/Rituxan]	—	TERMINATED	2010-06	NCT01117129
Wyeth is now a wholly owned subsidiary of Pfizer	etanercept (EnbrelTM)	—	TERMINATED	2009-12	NCT00706797
Roche	methotrexate	Folate Analog Metabolic Inhibitor [EPC]	WITHDRAWN	2015-06	NCT01878318
Wyeth is now a wholly owned subsidiary of Pfizer	Etanercept + Methotrexate	—	WITHDRAWN	2010-06	NCT00783536

Showing 100 of 205 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Hangzhou Highlightll Pharmaceutical Co., Ltd	TLL-018	—	RECRUITING	2026-12-31	NCT06887127
mAbxience Research S.L.	MB04 (proposed biosimilar to etanercept)	—	RECRUITING	2025-10	NCT06596772
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-07	NCT05814627
Hangzhou Highlightll Pharmaceutical Co., Ltd	TLL-018	—	ACTIVE NOT RECRUITING	2026-01-15	NCT06020144
Lynk Pharmaceuticals Co., Ltd	LNK01001	—	ACTIVE NOT RECRUITING	2025-08-22	NCT06276998
Biocad	Levilimab	—	ACTIVE NOT RECRUITING	2024-09	NCT05800327
SetPoint Medical Corporation	Conventional Synthetic DMARD	—	ACTIVE NOT RECRUITING	2024-05-16	NCT04539964
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	ACTIVE NOT RECRUITING	2023-06-14	NCT04909801
AbbVie	Adalimumab	TNF	ACTIVE NOT RECRUITING	2017-10-27	NCT02629159
Celltrion	CT-P13 SC Auto-Injector	—	COMPLETED	2025-06-25	NCT06738719
Alfasigma S.p.A.	Filgotinib	—	COMPLETED	2025-05-16	NCT03025308
Alvotech Swiss AG	AVT05 (proposed biosimilar to golimumab)	—	COMPLETED	2024-03-04	NCT05842213
AO GENERIUM	Complarate®	—	COMPLETED	2024-01-05	NCT06475508
Celltrion	CT-P47	—	COMPLETED	2023-06-29	NCT05489224
Taisho Pharmaceutical Co., Ltd.	TS-152	—	COMPLETED	2023-04-28	NCT04077567
Jiangsu HengRui Medicine Co., Ltd.	SHR0302	—	COMPLETED	2023-01-30	NCT04333771
RemeGen Co., Ltd.	RC18 160 mg plus MTX	—	COMPLETED	2022-11-19	NCT03016013
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2022-08-08	NCT03155347
Dr. Reddy's Laboratories Limited	Experimental: Arm A: DRL_RI	—	COMPLETED	2022-01-26	NCT04268771
Zhejiang Hisun Pharmaceutical Co. Ltd.	HS628+MTX	—	COMPLETED	2021-09-14	NCT06048224
R-Pharm International, LLC	Olokizumab 64 mg SC q4w	—	COMPLETED	2021-09-01	NCT03120949
Fresenius Kabi SwissBioSim GmbH	MSB11456	—	COMPLETED	2021-08-31	NCT04512001
Pfizer	PF-06410293	—	COMPLETED	2021-06-22	NCT04230213
Astellas	Peficitinib	—	COMPLETED	2021-04-01	NCT03660059
Biocad	BCD-089	—	COMPLETED	2021-03-15	NCT04227366
Bio-Thera Solutions	BAT1806	—	COMPLETED	2021-01-05	NCT03830203
Sanofi	SAR153191 (REGN88)	—	COMPLETED	2020-12-31	NCT01146652
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2020-11-12	NCT01885078
Alvotech Swiss AG	—	—	COMPLETED	2020-07-08	NCT04224194
Shanghai Henlius Biotech	HLX01	—	COMPLETED	2020-04-05	NCT03522415
Celltrion	CT-P13	—	COMPLETED	2020-03-16	NCT03707535
Amgen	etanercept pre-filled syringe subcutaneous injection	—	COMPLETED	2019-12-06	NCT02373813
Celltrion	CT-P17 SC AI (adalimumab)	—	COMPLETED	2019-11-04	NCT04171414
Celltrion	CT-P17 SC	—	COMPLETED	2019-10-08	NCT03789292
R-Pharm International, LLC	Olokizumab	—	COMPLETED	2019-09-12	NCT02760433
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2019-08-14	NCT02955212
R-Pharm International, LLC	Olokizumab 64mg q4w	—	COMPLETED	2019-08-02	NCT02760407
Shanghai Biomabs Pharmaceutical Co., Ltd.	CMAB008	—	COMPLETED	2019-06-23	NCT03478111
AbbVie	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2019-06-13	NCT03086343
Nichi-Iko Pharmaceutical Co., Ltd.	NI-071	—	COMPLETED	2019-05-20	NCT02990806
Gilead	Filgotinib	—	COMPLETED	2018-10-05	NCT02886728
R-Pharm International, LLC	Olokizumab	—	COMPLETED	2018-08	NCT02760368
Gilead	Filgotinib	—	COMPLETED	2018-07-04	NCT02889796
UCB Biopharma S.P.R.L.	e-Device	—	COMPLETED	2018-07-02	NCT03357471
Biocad	BCD-055	—	COMPLETED	2018-07	NCT02762838
Fresenius Kabi SwissBioSim GmbH	MSB11022	—	COMPLETED	2018-05-28	NCT03052322
Celltrion	CT-P13	—	COMPLETED	2018-05-21	NCT03147248
Gilead	Filgotinib	—	COMPLETED	2018-03-20	NCT02873936
AbbVie	Methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2018-03-15	NCT02706873
LG Life Sciences	LBEC0101	—	COMPLETED	2017-12	NCT02715908
AbbVie	Methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2017-10-02	NCT02706951
Coherus Oncology, Inc.	CHS-0214	—	COMPLETED	2017-09	NCT02486939
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-08-03	NCT02720523
Astellas	Peficitinib	—	COMPLETED	2017-06-20	NCT02305849
Mabion SA	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2017-05	NCT02468791
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-05	NCT02265705
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-04-21	NCT02675426
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-04-03	NCT02706847
Pfizer	Tofacitinib	—	COMPLETED	2017-03-15	NCT02281552
Gema Biotech S.A.	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2017-03	NCT03332719
Momenta Pharmaceuticals, Inc.	M923	—	COMPLETED	2017-02-21	NCT02722044
Biocad	Acellbia	—	COMPLETED	2017-02	NCT02744196
Novartis	Adalimumab - GP2017	—	COMPLETED	2017-01-31	NCT02744755
Astellas	Peficitinib	—	COMPLETED	2017-01-23	NCT02308163
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2017-01-16	NCT02504268
Novartis	GP2015	—	COMPLETED	2016-12-29	NCT02638259
UCB Pharma SA	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-12	NCT02319642
Korea Otsuka Pharmaceutical Co., Ltd.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-11	NCT01197066
Sanofi	Sarilumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-11	NCT02373202
Roche	Tocilizumab (TCZ)	—	COMPLETED	2016-10-14	NCT01855789
Sanofi	Sarilumab SAR153191 (REGN88)	—	COMPLETED	2016-10	NCT02293902
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2016-10	NCT02011334
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-09-13	NCT02046616
Pfizer	PF-06410293	—	COMPLETED	2016-08-31	NCT02480153
Cinnagen	Adalimumab	TNF	COMPLETED	2016-08-17	NCT03172325
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-08-04	NCT02046603
Roche	Azathioprine	Purine Antimetabolite [EPC]	COMPLETED	2016-07-10	NCT01941095
Novartis	GP2013 - A Proposed biosimilar rituximab	—	COMPLETED	2016-07	NCT02514772
Pfizer	PF-06438179	—	COMPLETED	2016-06-29	NCT02222493
UCB Pharma SA, Belgium	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-06	NCT02151851
Roche	Non-Biologic DMARDs	—	COMPLETED	2016-05-26	NCT01987479
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-05-11	NCT01668966
Sanofi	Sarilumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-01-20	NCT02332590
Celltrion	CT-P10	—	COMPLETED	2016-01	NCT02149121
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-12	NCT02001987
Coherus Oncology, Inc.	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-10	NCT02115750
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-09-09	NCT01941940
Novartis	Secukinumab (AIN457)	—	COMPLETED	2015-09-09	NCT01377012
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-09	NCT02031471
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-09	NCT01734993
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-08	NCT01951170
UCB Pharma	Certolizumab Pegol + Methotrexate (MTX)	—	COMPLETED	2015-07	NCT01521923
Roche	DMARD	—	COMPLETED	2015-07	NCT01995201
Biocad	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2015-07	NCT01759030
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-07	NCT01988012
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-07	NCT01655381
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-06	NCT01664598
Sanofi	sarilumab SAR153191 (REGN88)	—	COMPLETED	2015-05	NCT02121210
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-05	NCT01772316
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2015-05	NCT01730456

Showing 100 of 248 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Citryll BV	[89Zr]Zr-CIT	—	RECRUITING	2026-10-01	NCT07147959
Toll Biotech Co. Ltd. (Beijing)	Group 1: TollB-001 100mg qd po; Group 2: TollB-001 200mg qd po; Group 3: TollB-001400mg qd po	—	RECRUITING	2026-12	NCT07408024
Surf Therapeutics	—	—	RECRUITING	2026-12	NCT07293871
AbbVie	Lutikizumab	—	RECRUITING	2027-02	NCT06972446
Citryll BV	CIT-013 low dose	—	RECRUITING	2027-04	NCT06567470
Elevara Medicines Limited	ELV001 25 mg	—	RECRUITING	2027-04-15	NCT07409103
Roche	Afimkibart	—	RECRUITING	2027-04-19	NCT07137598
Changchun GeneScience Pharmaceutical Co., Ltd.	GenSci120 150 mg	—	RECRUITING	2027-09	NCT07423533
AstraZeneca	AZD1163	—	RECRUITING	2027-11-12	NCT07276581
Artiva Biotherapeutics, Inc.	Allogeneic NK Cells	—	RECRUITING	2028-01	NCT06991114
Amgen	Inebilizumab	—	RECRUITING	2028-07-21	NCT06570798
Quell Therapeutics Limited	QEL-005	—	RECRUITING	2028-08	NCT07473154
Nkarta, Inc.	NKX019	—	RECRUITING	2028-10	NCT06733935
Novartis	Rapcabtagene autoleucel	—	RECRUITING	2028-11-01	NCT07048197
Roche	Afimkibart	—	RECRUITING	2033-07-08	NCT07620392
Changchun GeneScience Pharmaceutical Co., Ltd.	GenSci048	—	RECRUITING	2026-03-31	NCT06189495
SynAct Pharma Aps	AP1189, 40 mg	—	RECRUITING	2025-12	NCT06671054
Spyre Therapeutics, Inc.	SPY002-072	—	ACTIVE NOT RECRUITING	2026-10-31	NCT07148414
Avalyn Pharma Inc.	AP01	—	ACTIVE NOT RECRUITING	2027-06	NCT06329401
Immunovant Sciences GmbH	IMVT-1402	—	ACTIVE NOT RECRUITING	2027-09	NCT06754462
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-3045 Injection	—	ACTIVE NOT RECRUITING	2026-04-21	NCT07233655
Novartis	VAY736 1ml PFS	—	ACTIVE NOT RECRUITING	2026-02-17	NCT06293365
AnaptysBio, Inc.	Rosnilimab	—	ACTIVE NOT RECRUITING	2024-11-29	NCT06041269
Beijing Baylx Biotech Co., Ltd.	hUC-MSC infusion (BC-U001)	—	ACTIVE NOT RECRUITING	2023-07-10	NCT04971980
XBiotech, Inc.	Natrunix 400 mg	—	NOT YET RECRUITING	2027-01-15	NCT06590090
Qilu Pharmaceutical Co., Ltd.	QLS12010	—	NOT YET RECRUITING	2028-03-05	NCT07377773
Celltex Therapeutics Corporation	autologous adipose derived stem cells	—	NOT YET RECRUITING	2024-12	NCT04170426
Eli Lilly	LY3871801	—	COMPLETED	2025-12-08	NCT05848258
Sanofi	SAR441566	—	COMPLETED	2025-06-18	NCT06073093
XBiotech, Inc.	Natrunix	—	COMPLETED	2024-10-31	NCT05363891
Celon Pharma SA	CPL409116	—	COMPLETED	2024-05-27	NCT05374785
Modern Biosciences Ltd	MBS2320 5 mg	—	COMPLETED	2023-12-28	NCT05460832
Aclaris Therapeutics, Inc.	ATI-450 50 mg oral tablet BID	—	COMPLETED	2023-09-05	NCT05279417
SynAct Pharma Aps	AP1189, 60 mg	—	COMPLETED	2023-08-28	NCT05604885
SynAct Pharma Aps	100 mg AP1189	—	COMPLETED	2023-07-20	NCT05516979
Tianjin Hemay Pharmaceutical Co., Ltd	Hemay007 800 mg QD group	—	COMPLETED	2023-06-22	NCT05247216
Beijing VDJBio Co., LTD.	Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection	—	COMPLETED	2023-06-02	NCT05957107
Abivax S.A.	ABX464	—	COMPLETED	2023-01-23	NCT04049448
Galapagos NV	Filgotinib	—	COMPLETED	2023-01-19	NCT02065700
Lynk Pharmaceuticals Co., Ltd	LNK01001 Dose A	—	COMPLETED	2022-12-29	NCT06099535
Hangzhou Highlightll Pharmaceutical Co., Ltd	TLL-018	—	COMPLETED	2022-12-19	NCT05133297
Bristol-Myers Squibb	branebrutinib	—	COMPLETED	2022-12-05	NCT04186871
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	KN019, 5mg/kg	—	COMPLETED	2022-07-28	NCT04038970
Pfizer	PF-06650833	—	COMPLETED	2022-02-07	NCT04413617
Navidea Biopharmaceuticals	Tc99m tilmanocept	—	COMPLETED	2022-01-21	NCT04947137
Eli Lilly	LY3462817	—	COMPLETED	2022-01-10	NCT04634253
Amgen	VIB4920	—	COMPLETED	2021-12-28	NCT04163991
SynAct Pharma Aps	50 mg AP1189	—	COMPLETED	2021-11-16	NCT04004429
Kang Stem Biotech Co., Ltd.	FURESTEM-RA Inj	—	COMPLETED	2021-10-05	NCT03618784
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-07-29	NCT02049138
Abivax S.A.	ABX464 50mg	—	COMPLETED	2021-04-27	NCT03813199
Galapagos NV	GLPG3970	—	COMPLETED	2021-03-26	NCT04577781
Navidea Biopharmaceuticals	Tc 99m tilmanocept	—	COMPLETED	2021-02-08	NCT03938636
Aclaris Therapeutics, Inc.	ATI-450	—	COMPLETED	2021-02-04	NCT04247815
Oscotec Inc.	SKI-O-703	—	COMPLETED	2020-10-13	NCT04057118
Hope Biosciences LLC	HB-adMSCs	—	COMPLETED	2020-08-17	NCT03691909
Galapagos NV	Filgotinib	—	COMPLETED	2020-08-14	NCT03926195
AbbVie	ABBV-3373	—	COMPLETED	2020-04-08	NCT03823391
AbbVie	Elsubrutinib	—	COMPLETED	2020-03-26	NCT03682705
Taiho Pharmaceutical Co., Ltd.	TAS5315 low dose	—	COMPLETED	2019-11-30	NCT03605251
Yungjin Pharm. Co., Ltd.	YRA-1909 low dose	—	COMPLETED	2019-11-19	NCT03275025
AstraZeneca	AZD9567	—	COMPLETED	2019-11-12	NCT03368235
Chong Kun Dang Pharmaceutical	CKD-506	—	COMPLETED	2019-09-30	NCT04204603
EMD Serono Research & Development Institute, Inc.	M2591 25 mg QD	—	COMPLETED	2019-09-23	NCT03233230
Roche	GDC-0853	—	COMPLETED	2019-07-17	NCT02983227
Jiangsu HengRui Medicine Co., Ltd.	SHR0302	—	COMPLETED	2019-04-16	NCT03254966
Rottapharm Biotech	CR6086	—	COMPLETED	2019-01-08	NCT03163966
Modern Biosciences Ltd	MBS2320	—	COMPLETED	2018-11-16	NCT03139136
Astellas	ASP5094	—	COMPLETED	2018-09-19	NCT03257852
Pfizer	PF-06650833	—	COMPLETED	2018-08-15	NCT02996500
Shanghai Henlius Biotech	HLX01	—	COMPLETED	2018-08	NCT03355872
Ablynx, a Sanofi company	ALX-0061	—	COMPLETED	2018-08	NCT02518620
Roche	GDC-0853	—	COMPLETED	2018-07-02	NCT02833350
Akros Pharma Inc.	JTE-051	—	COMPLETED	2018-06-25	NCT02919475
Light Chain Bioscience - Novimmune SA	NI-0101	—	COMPLETED	2018-06-20	NCT03241108
Eisai Co., Ltd.	E6011	—	COMPLETED	2018-05-16	NCT02960490
Bristol-Myers Squibb	BMS-986142	—	COMPLETED	2018-05-03	NCT02638948
Eisai Co., Ltd.	E6011	—	COMPLETED	2018-02-28	NCT02960438
Pfizer	PF-06651600	—	COMPLETED	2017-12-12	NCT02969044
Astellas	ASP1707	—	COMPLETED	2017-10-18	NCT02884635
Gilead	GS-9876	—	COMPLETED	2017-08-22	NCT02885181
Samsung Bioepis Co., Ltd.	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2017-08-03	NCT03193957
EMD Serono Research & Development Institute, Inc.	M2951	—	COMPLETED	2017-04-30	NCT02784106
UCB Celltech	Bimekizumab	—	COMPLETED	2017-04	NCT02430909
Bausch Health Americas, Inc.	SAN-300 0.5 mg/kg QW	—	COMPLETED	2017-02-23	NCT02047604
Dr. Reddy's Laboratories Limited	DRL_RI	—	COMPLETED	2016-11	NCT02296775
Ablynx, a Sanofi company	ALX-0061	—	COMPLETED	2016-08	NCT02309359
Ablynx, a Sanofi company	ALX-0061	—	COMPLETED	2016-07	NCT02287922
Takeda	Namilumab	—	COMPLETED	2016-05-11	NCT02379091
Mesoblast, Ltd.	Allogeneic Mesenchymal Precursor Cells	—	COMPLETED	2016-05	NCT01851070
Acerta Pharma BV	acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2016-05	NCT02387762
AbbVie	ABT-122	—	COMPLETED	2016-05	NCT02433340
Samsung Bioepis Co., Ltd.	Adalimumab PFS and Pen	—	COMPLETED	2016-03	NCT02565810
SinoMab BioScience Ltd	SM03	—	COMPLETED	2016-02-03	NCT04192617
Novartis	GP2013	—	COMPLETED	2016-01	NCT01274182
Bristol-Myers Squibb	CC-292	—	COMPLETED	2016-01	NCT01975610
Theramab LLC	TAB08	—	COMPLETED	2015-12	NCT01990157
AbbVie	adalimumab	TNF	COMPLETED	2015-09	NCT02141997
Maoxiang Group Jilin Pharmaceutical Co., Ltd.	Fang yi qing feng shi granule	—	COMPLETED	2015-08	NCT02029599
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2015-07-02	NCT02066389

Showing 100 of 196 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sonoma Biotherapeutics, Inc.	SBT777101	—	RECRUITING	2026-11	NCT06201416
Kali Therapeutics, Inc.	KT501	—	RECRUITING	2027-02	NCT07234773
Gilead	GS-0151	—	RECRUITING	2027-03	NCT06902519
Adicet Therapeutics	ADI-001	—	RECRUITING	2027-03-30	NCT07100873
AstraZeneca	AZD5492	—	RECRUITING	2027-05-05	NCT06916806
Bristol-Myers Squibb	BMS-986454	—	RECRUITING	2027-06-28	NCT07171983
Lifordi Immunotherapeutics, Inc.	LFD-200	—	RECRUITING	2027-07-16	NCT07207954
Seismic Therapeutic AU Pty Ltd	S-4321	—	RECRUITING	2027-09	NCT07455578
Capstan Therapeutics	CPTX2309	—	RECRUITING	2027-11	NCT06917742
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-038	—	RECRUITING	2027-12	NCT06857227
Cullinan Therapeutics Inc.	CLN-978	—	RECRUITING	2027-12-30	NCT06994143
Shenzhen MagicRNA Biotechnology Co., Ltd	HN2301 injection	—	RECRUITING	2027-12-31	NCT06801119
AstraZeneca	AZD0120	—	RECRUITING	2028-02-22	NCT07295847
SciRhom GmbH	SR-878	—	RECRUITING	2028-02-29	NCT07433335
Eli Lilly	LY4213663	—	RECRUITING	2028-03	NCT07258849
Eli Lilly	LY4298445	—	RECRUITING	2028-03	NCT07276958
Novartis	PIT565	—	RECRUITING	2028-05-15	NCT07029555
Xencor, Inc.	Plamotamab	—	RECRUITING	2028-06	NCT07230353
AstraZeneca	Surovatamig	—	RECRUITING	2028-06-27	NCT07201558
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	CC-97540	—	RECRUITING	2028-08-29	NCT05869955
Philogen S.p.A.	F8IL10	—	RECRUITING	2028-09-30	NCT07245992
AbbVie	ABBV-519	—	RECRUITING	2029-01	NCT07607964
Sanofi	SAR448501	—	RECRUITING	2029-06-25	NCT06647069
Merck	MK-1045	—	RECRUITING	2029-07-16	NCT07363590
Changchun GeneScience Pharmaceutical Co., Ltd.	GenSci120	—	RECRUITING	2026-07-05	NCT07040930
China Immunotech (Beijing) Biotechnology Co., Ltd.	YTS109 cell	—	RECRUITING	2026-05-19	NCT06978647
LAPIX Therapeutics Inc.	LPX-TI641	—	RECRUITING	2025-12-15	NCT06628206
Shanghai Qilu Pharmaceutical Research and Development Center LTD	QLS12010	—	RECRUITING	2025-12	NCT06946641
ILAb Co., Ltd.	IA-14069	—	RECRUITING	2025-11	NCT05533372
Zenas BioPharma (USA), LLC	ZB002	—	RECRUITING	2025-07	NCT05638854
Candid Therapeutics	CND261	—	ACTIVE NOT RECRUITING	2027-06-01	NCT07052032
Mabscale, LLC	Rituximab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2024-11	NCT06175338
Kali Therapeutics, Inc.	KT502	—	NOT YET RECRUITING	2027-12	NCT07564154
Baylx Inc.	hUC-MSC suspension	—	NOT YET RECRUITING	2027-12-31	NCT03828344
Otsuka Pharmaceutical Development & Commercialization, Inc.	HBM7020	—	NOT YET RECRUITING	2028-11-20	NCT07649265
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-3045 Injection	—	COMPLETED	2026-03-31	NCT07200596
Neutrolis	NTR1011	—	COMPLETED	2026-02-17	NCT07237659
AstraZeneca	AZD6912	—	COMPLETED	2025-10-16	NCT06115967
Artivila (Shenzhen) Innovation Center, Ltd	ARD-885 Tablets	—	COMPLETED	2025-08-14	NCT07266207
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-3045 Injection	—	COMPLETED	2025-06-17	NCT06883695
Shanghai Kanda Biotechnology Co., Ltd.	KD6005	—	COMPLETED	2025-01-10	NCT06213259
Lipum AB	SOL-116	—	COMPLETED	2024-11-28	NCT05576012
Kashiv BioSciences, LLC	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2024-10-16	NCT06929039
Novartis	ianalumab	—	COMPLETED	2024-07-18	NCT03574545
Chengdu Zenitar Biomedical Technology Co., Ltd	ZL-82 12.5mg	—	COMPLETED	2024-01-28	NCT06055023
Jiangsu vcare pharmaceutical technology co., LTD	VC005 tablets	—	COMPLETED	2023-10-18	NCT05874622
Sanofi	SAR441566	—	COMPLETED	2023-10-15	NCT05844735
Teijin America, Inc.	TCK-276	—	COMPLETED	2023-07-20	NCT05437419
Sanofi	SAR441566	—	COMPLETED	2023-07-17	NCT05858788
UCB Biopharma SRL	Pharmacokinetics of certolizumab pegol	—	COMPLETED	2023-05-23	NCT04163016
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQH3821 tablets	—	COMPLETED	2023-05-20	NCT05380934
Johnson & Johnson	JNJ-67484703	—	COMPLETED	2023-05-18	NCT04985812
Jiangsu HengRui Medicine Co., Ltd.	SHR0302 Tablets	—	COMPLETED	2022-08-18	NCT05392127
Jiangsu HengRui Medicine Co., Ltd.	itraconazole、 SHR0302 tablets	—	COMPLETED	2022-07-11	NCT05404724
R-Pharm International, LLC	Olokizumab	—	COMPLETED	2022-06-08	NCT04246762
LISCure Biosciences	LB-P6	—	COMPLETED	2022-04-01	NCT05053165
Longevity Inc.	Proximod	—	COMPLETED	2022-02-16	NCT06361199
Pfizer	PF-06835375	—	COMPLETED	2022-02-15	NCT03334851
UCB Biopharma SRL	Certolizumab pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2022-01-24	NCT04740814
Beijing VDJBio Co., LTD.	IL-6R Monoclonal Antibody Injection 4mg/kg	—	COMPLETED	2021-10-27	NCT05232396
Oryn Therapeutics, LLC	Low dose ORTD-1	—	COMPLETED	2021-10-12	NCT04286789
Jiangsu HengRui Medicine Co., Ltd.	SHR0302、[14C]SHR0302	—	COMPLETED	2021-09-19	NCT05047341
Gilead	Atorvastatin	—	COMPLETED	2021-01-13	NCT04608344
Daewon Pharmaceutical Co., Ltd.	DW1809-T2	—	COMPLETED	2020-09-08	NCT05214690
Daewon Pharmaceutical Co., Ltd.	DW1809	—	COMPLETED	2020-09-07	NCT05214677
Taizhou Mabtech Pharmaceutical Co.,Ltd	Infliximab	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2020-06-15	NCT04779892
Fountain Biopharma Inc.	FB704A	—	COMPLETED	2020-05-27	NCT03890302
Fresenius Kabi SwissBioSim GmbH	40 mg MSB11022	—	COMPLETED	2020-03-17	NCT04018599
Amgen	Rozibafusp Alfa	—	COMPLETED	2019-10-17	NCT03156023
Bio-Thera Solutions	BAT1806 injection	—	COMPLETED	2019-07-17	NCT03606876
Chong Kun Dang Pharmaceutical	D569 Tab.	—	COMPLETED	2019-04-05	NCT03858725
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2019-04-02	NCT03714022
Chong Kun Dang Pharmaceutical	XELJANZ 5Mg Tablet	—	COMPLETED	2019-03-29	NCT03868072
Boryung Pharmaceutical Co., Ltd	BR9001	—	COMPLETED	2019-03-18	NCT03718611
Gilead	Filgotinib	—	COMPLETED	2018-08-09	NCT03417778
Amgen	VIB4920	—	COMPLETED	2018-05-21	NCT02780388
Archigen Biotech Limited	SAIT101	—	COMPLETED	2018-04-30	NCT02819726
Hanlim Pharm. Co., Ltd.	HL237	—	COMPLETED	2018-03-19	NCT03278470
Innocare Pharma Australia Pty Ltd	ICP-022	—	COMPLETED	2018-02-05	NCT03189017
Novartis	VAY736	—	COMPLETED	2018-01-22	NCT02675803
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-12-19	NCT03262740
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-11-05	NCT03131973
Longevity Inc.	Proximod	—	COMPLETED	2017-11-01	NCT06361186
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-09-22	NCT03245515
AstraZeneca	AZD9567 10 mg	—	COMPLETED	2017-09-11	NCT02760316
Astellas	ASP5094	—	COMPLETED	2017-09-07	NCT02698657
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-08-16	NCT02705989
Philogen S.p.A.	F8IL10	—	COMPLETED	2017-04	NCT02076659
Novartis	CFZ533	—	COMPLETED	2017-02-03	NCT02089087
Navidea Biopharmaceuticals	Tilmanocept	—	COMPLETED	2016-12	NCT02683421
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-10	NCT02019602
AstraZeneca	AZD9567 Monohydrat	—	COMPLETED	2016-09-26	NCT02512575
Gilead	Tirabrutinib	—	COMPLETED	2016-09-01	NCT02626026
Astellas	ASP1707	—	COMPLETED	2016-08-30	NCT02867306
Bristol-Myers Squibb	BMS-986142 200mg	—	COMPLETED	2016-08	NCT02762123
OSE Immunotherapeutics	FR104	—	COMPLETED	2016-06	NCT02800811
Takeda	—	—	COMPLETED	2016-04-05	NCT02528786
Oscotec Inc.	SKI-O-703 capsule	—	COMPLETED	2016-03	NCT02717988
Sanofi	sarilumab SAR153191 (REGN88)	—	COMPLETED	2016-03	NCT02017639
Sanofi	sarilumab SAR153191 (REGN88)	—	COMPLETED	2016-03	NCT02404558

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Rheumatoid Arthritis

TNF-alpha (20)

Novel Rheumatoid Arthritis Drugs by Company (New molecular entities)

10 companies have an FDA-approved novel drug for Rheumatoid Arthritis.

Reformulations (23 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Rheumatoid Arthritis Drug Targets

Molecular targets of approved and investigational Rheumatoid Arthritis drugs — 18 targets tracked.

TNF 20 COX-2 14 COX-1 10 IL-6R 5 Dihydrofolate reductase 4 CD20 4 JAK1 4 JAK2 4 TYK2 2 H+/K+-ATPase 1 ACTH 1 Melanocortin receptors 1 IL1R1 1 IL-1alpha 1 IL-1beta 1 +3 more

Biosimilars (19 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.